Upjohn

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Retrieved on: 
Thursday, January 4, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
  • Dr. Sonia Quaratino, current EVP, Chief Medical Officer is appointed to the Executive Board.
  • Arvind Sood joins the Company in a newly created position of Executive Vice President, Innate Pharma SA and President of US Operations.
  • “We are taking steps to position Innate Pharma for future success by significantly strengthening our Executive Board now comprising Yannis, Sonia and Arvind,” said Hervé Brailly, interim Chief Executive Officer.

Rajiv Malik to Retire as President of Viatris Effective April 1, 2024

Retrieved on: 
Friday, October 20, 2023

(NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company effective April 1, 2024.

Key Points: 
  • (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company effective April 1, 2024.
  • Prior to Viatris, Malik served as president of Mylan, which he first joined in 2007 following the Company acquiring a controlling stake in Matrix Laboratories Limited, where he served as chief executive officer from 2005 to 2008.
  • Malik will continue to serve on the Viatris Board of Directors.
  • Robert J. Coury , Executive Chairman of Viatris, said, "There are not enough words to express how much Rajiv Malik as both a partner and a leader has meant to me, first at Mylan and now Viatris.

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations

Retrieved on: 
Tuesday, September 5, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230905869419/en/
    Ambaw Bellete, President and Chief Operating Officer, CG Oncology (Photo: Business Wire)
    “CG Oncology is at an important stage in our growth, advancing our late-stage clinical pipeline to address unmet medical needs in bladder cancer.
  • Ambaw, Swapnil and Vijay bring decades of experience and proven track records in developing immunotherapy agents from research to commercialization,” said Arthur Kuan, Chief Executive Officer, CG Oncology.
  • Previously, Vijay was the VP, Clinical Development and Medical Affairs and a member of the executive leadership team at AVEO.
  • He was also SVP of Scientific Affairs at FerGene, leading Medical Affairs, Clinical Operations, Regulatory and Clinical Development.

Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year

Retrieved on: 
Monday, May 22, 2023

PITTSBURGH, May 22, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that as a result of the strength and stability that Viatris has achieved since its formation in 2020, including its ninth consecutive quarter of solid execution and performance, as well as the successful completion of the integration of its two legacy companies, Robert J. Coury, the key architect behind Viatris' unique and powerful global platform, will once again transition his role, this time from his current position of Executive Chairman to Chairman Emeritus and Senior Strategic Advisor to the board and management following the company's 2023 annual meeting of shareholders. The annual meeting for 2023 is anticipated to occur in mid-December of this year, at which time Mr. Coury will not be standing for re-election.

Key Points: 
  • The annual meeting for 2023 is anticipated to occur in mid-December of this year, at which time Mr. Coury will not be standing for re-election.
  • This will not only ensure a smooth transition but also help limit potential business or strategic disruptions.
  • The Viatris board will select a new independent chair of the board who will be announced in the coming months and whose tenure is intended to begin following the 2023 annual meeting.
  • I want to sincerely thank each and every one of them for their commitment and partnership.

Cellarity Strengthens Executive Leadership Team

Retrieved on: 
Tuesday, April 11, 2023

The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.

Key Points: 
  • The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.
  • These new leadership appointments will allow Cellarity to accelerate development of its platform and progress its pipeline programs towards the clinic.
  • “Their appointments are a great complement to the already well experienced senior leadership team which includes Parul Doshi, recently promoted to Chief Data Officer.
  • Prior to joining Cellarity, he was previously Executive Medical Director in Clinical Development at Forma Therapeutics (acquired by Novo Nordisk) where he led their flagship sickle cell disease program.

Deloitte's CFO Program Names Frank D'Amelio as CFO-in-Residence

Retrieved on: 
Wednesday, January 18, 2023

"Deloitte's CFO Program has long been recognized for its prestige in advising current and future finance leaders through the challenges of a continually evolving business landscape.

Key Points: 
  • "Deloitte's CFO Program has long been recognized for its prestige in advising current and future finance leaders through the challenges of a continually evolving business landscape.
  • D'Amelio's responsibilities will range broadly, including playing a key role in CFO Transition Lab™ sessions, CFO Forums, Deloitte's annual CFO Vision™ conference, and the CFO Program's Next Generation CFO Academies .
  • Further, he will lend his experience and insights to Deloitte's quarterly CFO Signals™ survey and CFO 4Sight webinar, and biweekly CFO Insights series .
  • We are thrilled to formally welcome Frank to the CFO Program team as our CFO-in-residence."

Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors

Retrieved on: 
Thursday, December 29, 2022

PITTSBURGH, Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors. Smith and Finney fill the vacancies created by the retirement of Neil Dimick and Ian Reid.

Key Points: 
  • PITTSBURGH, Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors.
  • Coury continued, "We are also pleased to welcome Scott Smith and Elisha Finney to the board.
  • We look forward to working with both Scott and Elisha and the contributions that each will bring to our board."
  • Ian Read stated, "I have sincerely appreciated my time on the Viatris board of directors since the Combination.

Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent

Retrieved on: 
Thursday, November 10, 2022

(NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's Symbicort patent, U.S. Patent No.

Key Points: 
  • (NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's Symbicort patent, U.S. Patent No.
  • Today's decision marks the fourth Symbicort patent to be found either not infringed or invalid.
  • In May, after Viatris and Kindeva won an appeal, AstraZeneca stipulated that the Company's budesonide/formoterol fumarate dihydrate products would not infringe U.S. Patent Nos.
  • Such forward looking statements may include statements about the decision bythe U.S. District Court for the Northern District of West Virginia that AstraZeneca's Symbicort patent, U.S. Patent No.

Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event

Retrieved on: 
Monday, November 7, 2022

Together, the two acquisitions have an aggregate purchase price of approximately $700-$750 million which Viatris expects to fund with cash on hand.

Key Points: 
  • Together, the two acquisitions have an aggregate purchase price of approximately $700-$750 million which Viatris expects to fund with cash on hand.
  • Ophthalmology is one of the key therapeutic areas of focus that the Company identified in February.
  • Viatris Executive Chairman Robert J. Coury said: "Two years into our journey as Viatris, I am extremely pleased with the strength and execution of our business.
  • We are pleased to announce this morning our agreements to acquire two high quality businesses to form a new ophthalmology franchise within Viatris.

GNS Appoints John Maraganore as Chair of the Board

Retrieved on: 
Thursday, November 3, 2022

Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.

Key Points: 
  • Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.
  • From his roles at Biogen to Millennium Pharmaceuticals to Alnylam, John is the rare individual who has brought innovation to market.
  • "I would like also to thank our outgoing Board Chair, Timothy Thompson, who will remain on the board, for his dedication and valuable service to GNS."
  • Dr. Maraganore is Chair Emeritus and a member of the Board of the Biotechnology Innovation Organization (BIO), where he was Chair from 2017-2019.